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survival and overall survival were estimated using the Kaplan-
Meier method. 
Results: Median age was 85 years (range 68-97 years). There 
were 31 males and 24 females. Four deaths occurred during 
radiotherapy unrelated to treatment (3 from pneumonia and 
1 from urinary sepsis).  
Genito-urinary grade 2 and grade 3 acute toxicity was seen in 
20% and 10% respectively. Gastro-intestinal grade 2 and grade 
3 acute toxicity was seen in 9.5 % and <1% respectively. No 
grade 4 genito-urinary or gastro-intestinal toxicity was seen. 
16% reported other grade 2 acute toxicity and <1% reported 
other grade 3 acute toxicity.  
Grade 2 late toxicity (any) at 6 and 12 months was seen in 
19% and 10.5% respectively. Any grade 3 late toxicity at 6 and 
12 months was seen 6.5% and 5% respectively. 
Local control at 3 months following radiotherapy was 88% 
(95%CI 64%-99%). Local progression free survival at 1 year was 
88% (95%CI 77%-100%) and overall survival at 1 year was 64% 
(95% CI 50%-77%).  
Conclusions: Hypofractionated radiotherapy delivered with a 
plan of the day IGART approach offers good local control with 
acceptable toxicity in a patient population not suitable for 
radical bladder treatment. This strategy is now being 
evaluated in a randomised multi-centre trial (HYBRID study; 
hypofractionated bladder radiotherapy with or without image 
guided adaptive planning).  
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Purpose/Objective: Stereotactic body radiotherapy (SBRT) is 
used increasingly for the treatment of localised prostate 
cancer (LPC). Although there is a significant body of data on 
efficacy, few published studies have assessed toxicity more 
than once during the first 12 weeks after treatment, 
potentially underestimating acute toxicity. This information 
is essential for informed patient consent. We aimed to 
accurately define the toxicity profile by prospective two-
weekly assessment. 
Materials and Methods: Patients were treated using the 
Cyberknife® system with a dose of 36.25Gy / 5# (PTV V36.25 
Gy > 95%; prostate V40 Gy > 95%). Patients were treated on 
alternate or consecutive week days (range: 5-12 days). No 
patients received hormonal therapy. IPSS and RTOG toxicity 
was prospectively assessed at 2, 4, 6, 8, 10 and 12 weeks 
from start of treatment. Thereafter, patients were assessed 
every 3 months for the first 2 years, then 6 monthly. This 
study was given prospective approval by our institutional 
Clinical Research Committee. 
Results: Forty consecutive patients were treated; 5 low, 34 
intermediate, and 1 high NCCN risk. Median follow up was 21 
months (range: 3-38). Median IPSS score at baseline was 6 
(IQR: 4-11). Peak median IPSS score was recorded at two 
weeks (17; IQR: 8-22), returning to baseline by 4-6 weeks. 
The incidence of acute grade 2+ RTOG GU and GI toxicity was 
25% (10) and 20% (8), respectively, peaking at 2-3 weeks. 
Forty eight percent (19) received an α-blocker, either 
prophylactically (13%, 5 patients) or for urinary symptoms. 
One case of grade 3 GU toxicity occurred at 8 weeks due to 
mild transient haematuria. A single case of grade 3 GI 
toxicity occurred at 4 weeks due to a small amount of faecal 
incontinence. All acute toxicity had settled to grade 0-1 by 
week 10. No difference in acute toxicity was observed 
between patients having daily or alternate daily treatment. 
Incidence of late grade 2+ toxicity was 5% (2) for GU domain 
and 5% (2) for GI domain. Median PSA at baseline, 12 months 
and 24 months was 9, 0.96 and 0.65, respectively. 
Conclusions: Acute toxicity from SBRT for LPC peaks earlier 
than that of conventionally fractionated radiotherapy, but 
resolved rapidly and completely. Infrequent assessment risks 
underestimation of toxicity in this emerging treatment. SBRT 
should be evaluated in randomised trials, such as the PACE 
study, against current standards of care. 
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Purpose/Objective: Clinical data suggest that large radiation 
fractions are biologically superior to smaller fraction sizes in 
prostate cancer radiotherapy. Hypofractionated prostate 
stereotactic body radiotherapy aims to minimize the dose to 
the surrounding critical normal structures while delivering a 
large dose to the target volume. The CyberKnife is an 
appealing delivery system for hypofractionated radiosurgery 
due to its ability to deliver highly conformal radiation and to 
track and adjust for prostate motion in real-time. We 
compared outcomes in intermediate to high risk prostate 
cancer patients treated with cyberknife for boost after 
internsity modulated radiation therapy (IMRT) or three-
dimensional conformal radiation therapy (3-DRT).  
Materials and Methods: This study was based on a 
retrospective chart review analysis of the 46 patients treated 
with CyberKnife radiotherapy for localized prostate cancer. 
27 patients treated with 3DRT to a dose of 45 Gy in 25 
fractions and 19 patients with IMRT to same dose and all 
patients received a boost by the CyberKnife at dose of 21 Gy 
in 3 fractions. The acute toxicities were recorded using the 
RTOG acute toxicity scale and the Common Terminology 
Criteria for Adverse Events, version 3.0.  
Results: All 46 patients finished planed radiation therapy 
without any severe complication. The median follow-up for 
patients was 38 months (range 6 - 56 months). There were 
two biochemical failures in high risk patients in 3-DRT+CK 
and one in IMRT+CK group. The 3-year actuarial biochemical 
progression-free survival was 92.3% for 3-DRT+CK and 94.8% 
for IMRT+CK (p=0.752). There were no acute Grade 3 or 4 GI 
toxicities. Late Grade 3 GI toxicity, rectal bleeding, was 
noted in 2 patient in high risk group (7.4%) only in 3-DRT+CK 
group but bleeding was stopped with 3 times laser 
coagulation in one patients. There was acute Grade 3 urinary 
frequency in one patient (3.74%) of high risk group of 3-
DRT+CK group . There were no late grade 3 to 4 GU toxicity 
in both group.  
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Conclusions: Hypofractionated stereotactic body 
radiotherapy with CyberKnife boost and pelvis radiation 
therapy for prostate cancer has an acceptable toxicity profile 
and favorable biochemical response in both 3-DRT+CK and 
IMRT+CK group, but toxicity was more favorable tendency in 
IMRT+CK treatment group. Additional follow-up is required to 
better evaluate potential toxicity and control rate. 
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Purpose/Objective: The aim of the study was to assess the 
quality of life in prostate cancer patients during the 
stereotactic body radiotherapy treatment. 
Materials and Methods: 91 low and intermediate risk 
localized prostate adenocarcinoma patients were irradiated 
using the CyberKnife Radiosurgical System. The prescription 
dose was 35- 36,25 Gy in five fractions. The assessment of 
the quality of life was measured using the EORTC QLQ-C30 (v 
3.0) questionnaire and a prostate-specific EORTC QLQ-PR25 
module. Patients were asked to fill the form before and at 
the end of the treatment. The further study is designed to 
assess the quality of life during the 2-year follow-up. 
Results: No significant differences were seen in comparison 
of questions measuring Global Health Status before and after 
the treatment (normalized score 60 vs 57). Among all the 
assessed symptoms only the intensification of urinary bothers 
and diarrhoea were found as statistically significant. The 
quality of sexual life has not significantly decreased, however 
among the sexual-specific questions the highest percentage 
of missing data was observed (39%). The tendency of 
improving the level of emotional functioning after the 
radiotherapy was also noticed. 
Conclusions: The study revealed that in spite of 
intensification of urinary and bowel symptoms the global 
quality of life has not significantly changed during the 
treatment what makes the CyberKnife stereotactic body 
radiotherapy a well-tolerated method.  
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Purpose/Objective: Features of high-dose-rate 
brachytherapy (HDR) correspond to biological data that 
suggests hypofractionation as the most suitable way to 
achieve high-dose treatment of prostate cancer. Evaluated 
were our results of combined HDR-boost treatment (HDR-B) 
and 3-dimensional conformal external beam radiotherapy 
(3DCRT). 
Materials and Methods: From October 2006 through April 
2011 88 patients with localized prostate cancer received 
HDR-B of either 3×7 Gy (27/88 patients) or 3×6 Gy (61/88 
patients) delivered through one (80/88 patients) or two (8/88 
patients) procedures and CT (30/88 patients) or MR (58/88 
patients) based planning. Together with 50.4 Gy of 3DCRT 
that in 68/88 patients with increased risk for regional 
metastases (2/3PSA + ((GS – 6) ×10) >13%) included also 
pelvic nodes. Androgen deprivation (AD) was given for a 
mean 24 months to 81/88 patients. Results were compared to 
similar group of 62 successive patients treated solely with 
3DCRT (TD 75.6 Gy/42fx) and AD (in 58/62 patients for mean 
33 months). 18F–Choline PET-CT was used to identify site of 
biochemical relapse. 
Results: HDR-B treatment distinguished by significantly lower 
local failure rate: 8/62 vs. 1/88 patients (p=0.002) – the 
improvement in local control was most distinctive in high-risk 
patients: 7/43 vs. 1/40 patients (p=0.024). Improvement in 5-
year progression-free survival was not significant (97% and 
90% for low/intermediate-risk and 82% and 75% for high-risk 
patients). None of the treatment parameters inclusive dose 
of treatment influenced results of HDR-B. 
Conclusions: Results proved the efficacy of HDR-B. PET-CT 
gives insight of the site of biochemical relapse that is needed 
for the refinement of HDR-B. 
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Purpose/Objective: Over 1,200 Canadian MSM are diagnosed 
with prostate cancer (PCa) each year, and over 8,700 MSM 
have been living with the disease for the past 10 years. With 
early PCa diagnosis, the impact of PCa on sexual function has 
become increasingly important. However, there are few 
studies examining the impact of PCa treatments on sexual 
function for MSM.  
Materials and Methods: MSM were recruited through 
advertising in newspapers, doctors' offices, and word of 
mouth. Participants under the age of 70 treated with curative 
intent for non-metastatic prostate cancer were eligible. 
Individual 45-60 minute semi-structured interviews took 
place face to face or via internet-based video conferencing. 
Sexual function, sexual quality of life, and relationships 
before and after treatment, were discussed. Interviews were 
recorded, transcribed, coded independently by the 
investigators, and analyzed with NVivo. 
Results: Forty three participants were screened with fifteen 
eligible participants (age range = 58-69, mean = 65). The age 
of diagnosis ranged from 55-67 (mean = 58) and the mean 
time from treatment to interview was 6.6 years. Treatment 
modalities included radical prostatectomy (n=8), external 
beam radiation (n = 3), brachytherapy (n = 3), and combined 
radical prostatectomy and external beam radiation (n=1). 
